Why You Can't Sleep on Peptides

Your body runs on glucose the way a car runs on fuel, and the overnight stretch between dinner and breakfast is the longest it ever goes without a refill.

To manage that gap, your liver stores glucose in a form called glycogen, and it slowly releases it through the night to keep your blood sugar stable enough for your brain to stay in deep sleep. When that stored fuel runs low, your body treats it as a threat and activates what you could think of as the emergency generator. It releases cortisol and adrenaline to trigger something called gluconeogenesis, which is the process of making new glucose from non-carbohydrate sources like amino acids and fat. That release is what wakes you up at 2 or 3 in the morning, heart beating a little faster, mind suddenly alert, unable to get back down. It is not insomnia. It is a metabolic alarm.

Peptides can push you toward that alarm through two completely different mechanisms, and understanding which one applies to you changes what you actually do about it.

The first mechanism comes from the incretin class of drugs, which includes compounds like semaglutide, tirzepatide, and retatrutide. These molecules work by mimicking gut hormones that tell your brain you are full and your pancreas to manage insulin more carefully. The result is a dramatic reduction in appetite that is not subtle. In the phase 2 trial for retatrutide, participants at the highest dose lost an average of 24.2 percent of their body weight over about 11 months, and the primary driver of that loss was how much less they were eating.

Here is where the sleep problem starts. When a drug suppresses your appetite that aggressively, most people undereat without realizing it. Not intentionally, not even noticeably in the moment, because the drug has quieted the hunger signals that would normally tell them they need more food. Less food going in during the day means less glycogen stored going into the night, which means your blood sugar has a shorter runway before it drops into the range where your body calls the alarm.

The second mechanism is entirely different and comes from the growth hormone secretagogue class, which includes things like CJC-1295, ipamorelin, and tesamorelin. These compounds work by stimulating your pituitary gland to release growth hormone, and most people take them before bed because the largest natural pulse of growth hormone happens during the first few hours of deep sleep anyway. The idea is to amplify that pulse and let it do its work overnight.

The problem is that growth hormone and insulin are physiological opponents. Growth hormone is anti-insulin, meaning it actively reduces insulin's ability to get glucose out of your blood and into cells, particularly in the liver. The mechanism involves increased free fatty acid flux, which means growth hormone causes fat tissue to release fatty acids into circulation, and those fatty acids compete with glucose for uptake in muscle and other tissues, which drives blood glucose up and forces the liver to reduce how much it clears. Researchers studying this found that nocturnal spikes in growth hormone were directly responsible for what is called the dawn phenomenon, and when they suppressed those GH spikes using somatostatin, the dawn phenomenon disappeared entirely. When they then artificially restored the GH spikes, it came back, and hepatic glucose production increased by approximately 30 percent.

So a GH secretagogue injected before bed fires a hormone pulse that antagonizes insulin at the exact moment your body is trying to manage blood sugar through a long overnight fast, and the swings that creates can be enough to trigger the same cortisol rescue response.

If you are on both an incretin and a GH secretagogue at the same time, both mechanisms are running simultaneously. The incretin has reduced how much you ate during the day, so your glycogen stores are lower going into the night, and then the GH pulse is creating additional blood sugar instability on top of depleted reserves.

Knowing which mechanism is driving the problem matters because the fixes are different.

If you are on an incretin and you are waking up in the middle of the night, the first question to ask is whether you are actually eating enough during the day. Not enough in a vague sense, but enough total calories to fill your glycogen stores before you go to sleep. The drug is doing its job by killing your appetite, and your job is to make sure you are still hitting your targets even when you are not hungry. For people on low carb or ketogenic diets, the concern is not the carb restriction itself because the body does adapt to run on fat and produce glucose through gluconeogenesis when it is given enough total substrate to work with. The issue is when the drug suppresses appetite so effectively that total food intake drops low enough that there is nothing left for your body to work with either way.

If you are on a GH secretagogue and the timing of your injection is right before bed, try moving it two to three hours earlier in the evening. This shifts the GH pulse earlier in the night and gives your body more time to stabilize before you are in the deepest and most vulnerable stretch of sleep. A small snack before bed that is built around protein and fat, not sugar, can also help by giving your liver something to work with and slowing the rate of blood sugar decline through the night. This works as a buffer in both scenarios.

The reason this matters beyond just getting a full night of sleep is that the cortisol being released to rescue your blood sugar is itself a counter-regulatory hormone that raises glucose, increases fat storage around the midsection, and can blunt the very hormonal environment the GH secretagogue was meant to create in the first place. Waking up repeatedly in the early morning hours is not just an inconvenience. It is a sign that two systems in your body are working against each other, and the fix is almost always simpler than people expect once they understand which system is actually failing.

The peptide did not break your sleep. It revealed a gap in your metabolic foundation that was always going to matter, and now you know where to look.

---

References

1. Perriello G, De Feo P, Torlone E, et al. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 diabetes mellitus by decreasing hepatic and extrahepatic sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990;331:52-59. Finding: Suppressing nocturnal GH spikes with somatostatin abolished the dawn phenomenon; restoring GH spikes reproduced it. Hepatic glucose production increased approximately 30%. Source
2. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;302:152-177. Finding: GH antagonizes insulin's hepatic and peripheral effects via increased free fatty acid flux and uptake. Source
3. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;3896:514-526. Finding: 24.2% mean weight loss at 12mg dose; significant appetite suppression documented across all dose groups. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness